CytoDyn appoints board chairman
Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds
Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall
Global M&A By the Numbers: Q1 2022
Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes
CytoDyn Inc. appointed Scott Kelly as board chairman.
Kelly, who has served as a member of the company's board since April 2017, succeeds Anthony Caracciolo, who will continue as a director.
Vancouver, Wash.-based CytoDyn develops humanized monoclonal antibodies to treat and prevent HIV infection.